2081 related articles for article (PubMed ID: 28011833)
1. Human-induced pluripotent stem cell-derived cardiomyocytes from cardiac progenitor cells: effects of selective ion channel blockade.
Altomare C; Pianezzi E; Cervio E; Bolis S; Biemmi V; Benzoni P; Camici GG; Moccetti T; Barile L; Vassalli G
Europace; 2016 Dec; 18(suppl 4):iv67-iv76. PubMed ID: 28011833
[TBL] [Abstract][Full Text] [Related]
2. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents.
Ma J; Guo L; Fiene SJ; Anson BD; Thomson JA; Kamp TJ; Kolaja KL; Swanson BJ; January CT
Am J Physiol Heart Circ Physiol; 2011 Nov; 301(5):H2006-17. PubMed ID: 21890694
[TBL] [Abstract][Full Text] [Related]
3. Role of somatic cell sources in the maturation degree of human induced pluripotent stem cell-derived cardiomyocytes.
Pianezzi E; Altomare C; Bolis S; Balbi C; Torre T; Rinaldi A; Camici GG; Barile L; Vassalli G
Biochim Biophys Acta Mol Cell Res; 2020 Mar; 1867(3):118538. PubMed ID: 31472168
[TBL] [Abstract][Full Text] [Related]
4. Ion Channel Dysfunctions in Dilated Cardiomyopathy in Limb-Girdle Muscular Dystrophy.
El-Battrawy I; Zhao Z; Lan H; Li X; Yücel G; Lang S; Sattler K; Schünemann JD; Zimmermann WH; Cyganek L; Utikal J; Wieland T; Bieback K; Bauer R; Ratte A; Pribe-Wolferts R; Rapti K; Nowak D; Wittig J; Thomas D; Most P; Katus HA; Ravens U; Schmidt C; Borggrefe M; Zhou XB; Müller OJ; Akin I
Circ Genom Precis Med; 2018 Mar; 11(3):e001893. PubMed ID: 29545480
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of human-induced pluripotent stem cells derived from bone marrow cells, hair keratinocytes, and skin fibroblasts.
Streckfuss-Bömeke K; Wolf F; Azizian A; Stauske M; Tiburcy M; Wagner S; Hübscher D; Dressel R; Chen S; Jende J; Wulf G; Lorenz V; Schön MP; Maier LS; Zimmermann WH; Hasenfuss G; Guan K
Eur Heart J; 2013 Sep; 34(33):2618-29. PubMed ID: 22798560
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Batch Variations in Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes from 2 Major Suppliers.
Huo J; Kamalakar A; Yang X; Word B; Stockbridge N; Lyn-Cook B; Pang L
Toxicol Sci; 2017 Mar; 156(1):25-38. PubMed ID: 28031415
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
[TBL] [Abstract][Full Text] [Related]
8. Application of human induced pluripotent stem cell-derived cardiomyocytes sheets with microelectrode array system to estimate antiarrhythmic properties of multi-ion channel blockers.
Izumi-Nakaseko H; Hagiwara-Nagasawa M; Naito AT; Goto A; Chiba K; Sekino Y; Kanda Y; Sugiyama A
J Pharmacol Sci; 2018 Aug; 137(4):372-378. PubMed ID: 30126708
[TBL] [Abstract][Full Text] [Related]
9. Resolving the Reversed Rate Effect of Calcium Channel Blockers on Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and the Impact on In Vitro Cardiac Safety Evaluation.
Zeng H; Wang J; Clouse H; Lagrutta A; Sannajust F
Toxicol Sci; 2019 Feb; 167(2):573-580. PubMed ID: 30365015
[TBL] [Abstract][Full Text] [Related]
10. Human induced pluripotent stem cell-derived atrial cardiomyocytes recapitulate contribution of the slowly activating delayed rectifier currents IKs to repolarization in the human atrium.
Sönmez MI; Goldack S; Nurkkala E; Schulz C; Klampe B; Schulze T; Hansen A; Eschenhagen T; Koivumäki J; Christ T
Europace; 2024 Jun; 26(6):. PubMed ID: 38788213
[TBL] [Abstract][Full Text] [Related]
11. L-Type Calcium Channel Inhibition Contributes to the Proarrhythmic Effects of Aconitine in Human Cardiomyocytes.
Wu J; Wang X; Chung YY; Koh CH; Liu Z; Guo H; Yuan Q; Wang C; Su S; Wei H
PLoS One; 2017; 12(1):e0168435. PubMed ID: 28056022
[TBL] [Abstract][Full Text] [Related]
12. Electrical dysfunctions in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with an arrhythmogenic right ventricular cardiomyopathy.
El-Battrawy I; Zhao Z; Lan H; Cyganek L; Tombers C; Li X; Buljubasic F; Lang S; Tiburcy M; Zimmermann WH; Utikal J; Wieland T; Borggrefe M; Zhou XB; Akin I
Europace; 2018 Jun; 20(FI1):f46-f56. PubMed ID: 29566126
[TBL] [Abstract][Full Text] [Related]
13. Disease characterization using LQTS-specific induced pluripotent stem cells.
Egashira T; Yuasa S; Suzuki T; Aizawa Y; Yamakawa H; Matsuhashi T; Ohno Y; Tohyama S; Okata S; Seki T; Kuroda Y; Yae K; Hashimoto H; Tanaka T; Hattori F; Sato T; Miyoshi S; Takatsuki S; Murata M; Kurokawa J; Furukawa T; Makita N; Aiba T; Shimizu W; Horie M; Kamiya K; Kodama I; Ogawa S; Fukuda K
Cardiovasc Res; 2012 Sep; 95(4):419-29. PubMed ID: 22739119
[TBL] [Abstract][Full Text] [Related]
14. Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform.
Qu Y; Vargas HM
Toxicol Sci; 2015 Sep; 147(1):286-95. PubMed ID: 26117837
[TBL] [Abstract][Full Text] [Related]
15. Ontogenic development of cardiomyocytes derived from transgene-free human induced pluripotent stem cells and its homology with human heart.
Sequiera GL; Mehta A; Ooi TH; Shim W
Life Sci; 2013 Jan; 92(1):63-71. PubMed ID: 23142239
[TBL] [Abstract][Full Text] [Related]
16. Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
El-Battrawy I; Lan H; Cyganek L; Zhao Z; Li X; Buljubasic F; Lang S; Yücel G; Sattler K; Zimmermann WH; Utikal J; Wieland T; Ravens U; Borggrefe M; Zhou XB; Akin I
J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29574456
[TBL] [Abstract][Full Text] [Related]
17. Safety pharmacology studies using EFP and impedance.
Obergrussberger A; Juhasz K; Thomas U; Stölzle-Feix S; Becker N; Dörr L; Beckler M; Bot C; George M; Fertig N
J Pharmacol Toxicol Methods; 2016; 81():223-32. PubMed ID: 27084108
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of KCNJ2 in induced pluripotent stem cell-derived cardiomyocytes for the assessment of QT-prolonging drugs.
Li M; Kanda Y; Ashihara T; Sasano T; Nakai Y; Kodama M; Hayashi E; Sekino Y; Furukawa T; Kurokawa J
J Pharmacol Sci; 2017 Jun; 134(2):75-85. PubMed ID: 28615142
[TBL] [Abstract][Full Text] [Related]
19. Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes.
Rocchetti M; Sala L; Dreizehnter L; Crotti L; Sinnecker D; Mura M; Pane LS; Altomare C; Torre E; Mostacciuolo G; Severi S; Porta A; De Ferrari GM; George AL; Schwartz PJ; Gnecchi M; Moretti A; Zaza A
Cardiovasc Res; 2017 Apr; 113(5):531-541. PubMed ID: 28158429
[TBL] [Abstract][Full Text] [Related]
20. Electrophysiological mechanisms of vandetanib-induced cardiotoxicity: Comparison of action potentials in rabbit Purkinje fibers and pluripotent stem cell-derived cardiomyocytes.
Lee HA; Hyun SA; Byun B; Chae JH; Kim KS
PLoS One; 2018; 13(4):e0195577. PubMed ID: 29630634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
